Most Read Articles
4 days ago
Chocolate consumption is not associated with risk of coronary heart disease (CHD), stroke or both combined in postmenopausal women free of pre-existing major chronic disease, a study suggests.
Pearl Toh, 5 days ago
More intensive lowering of LDL-C levels was associated with a progressively greater survival benefit than less intensive approach, when the baseline LDL-C levels were ≥100 mg/dL, reveals a meta-analysis of 34 randomized trials.
4 days ago
Switching from thiazide diuretic to ipragliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitor, leads to improvements in metabolic parameters and body mass composition without affecting blood pressure in type 2 diabetes (T2D) patients, a recent study has found.
2 days ago
Adolescents who sleep longer and have higher sleep efficiency have a favourable cardiometabolic profile, including lower abdominal adiposity, lower systolic blood pressure and higher high-density lipoprotein cholesterol levels, as shown in a study.

Baricitinib may alter lipid profiles in rheumatoid arthritis patients

07 Mar 2018

Baricitinib treatment appears to be associated with increases in circulating lipid levels, including low-density lipoprotein (LDL) and high-density lipoprotein (HDL) cholesterol and triglyceride levels, but not in LDL-C:HDL-C ratio, according to a study.

Researchers analysed lipid data from phase II and III studies of oral baricitinib at 4-mg (n=997) and 2-mg (n=479) doses administered once daily in patients with moderate-to-severe active rheumatoid arthritis (RA). Additionally, they evaluated lipoprotein particle size and number and GlycA using nuclear magnetic resonance in one phase III study.

Pooled data revealed increased levels of total cholesterol, LDL-C, HDL-C and triglycerides following treatment with baricitinib. On the other hand, the drug did not significantly alter LDL-C:HDL-C ratio. Lipid levels plateaued by 12 weeks of treatment.

Nuclear magnetic resonance data showed that increases in HDL occurred across all particle sizes, whereas elevations in LDL were limited to larger particles, with small LDL particle levels decreasing. LDL increases were reversed in response to statin therapy.

The present data may reflect a positive impact on aspects of the lipid paradox observed in RA, researchers said.

Then again, additional studies investigating the effects of baricitinib on cholesterol and lipoprotein metabolism, as well as those evaluating cardiovascular event rates during long-term treatment, are warranted to further characterize the findings of the present study and their possible clinical implications, researchers added.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
4 days ago
Chocolate consumption is not associated with risk of coronary heart disease (CHD), stroke or both combined in postmenopausal women free of pre-existing major chronic disease, a study suggests.
Pearl Toh, 5 days ago
More intensive lowering of LDL-C levels was associated with a progressively greater survival benefit than less intensive approach, when the baseline LDL-C levels were ≥100 mg/dL, reveals a meta-analysis of 34 randomized trials.
4 days ago
Switching from thiazide diuretic to ipragliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitor, leads to improvements in metabolic parameters and body mass composition without affecting blood pressure in type 2 diabetes (T2D) patients, a recent study has found.
2 days ago
Adolescents who sleep longer and have higher sleep efficiency have a favourable cardiometabolic profile, including lower abdominal adiposity, lower systolic blood pressure and higher high-density lipoprotein cholesterol levels, as shown in a study.